Analysts Have Conflicting Sentiments on These Healthcare Companies: Stryker (SYK) and Cross Country Healthcare (CCRN)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Stryker (SYK – Research Report) and Cross Country Healthcare (CCRN – Research Report).
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Stryker (SYK)
In a report released today, Joanne Wuensch from Citi maintained a Buy rating on Stryker. The company’s shares closed last Thursday at $373.42.
According to TipRanks.com, Wuensch is a 4-star analyst with an average return of
Currently, the analyst consensus on Stryker is a Strong Buy with an average price target of $431.88, which is a 18.4% upside from current levels. In a report issued on October 30, RBC Capital also maintained a Buy rating on the stock with a $435.00 price target.
See the top stocks recommended by analysts >>
Cross Country Healthcare (CCRN)
Benchmark Co. analyst Bill Sutherland maintained a Hold rating on Cross Country Healthcare today. The company’s shares closed last Thursday at $10.87, close to its 52-week low of $9.58.
According to TipRanks.com, Sutherland is a 1-star analyst with an average return of
The word on The Street in general, suggests a Hold analyst consensus rating for Cross Country Healthcare.
Read More on SYK:
Disclaimer & DisclosureReport an Issue
- Stryker price target raised to $456 from $452 at Wells Fargo
- Stryker’s Strategic Growth Plans and Market Leadership Reinforce Buy Rating
- Stryker’s Strategic Growth and Innovation Drive: Buy Rating Affirmed
- Stryker’s Robust Growth Trajectory and Strategic Initiatives Justify Buy Rating
- Stryker’s Strong Market Position and Growth Potential Justify Buy Rating with $410 Price Target
